---
title: "Transtek released its first-quarter performance, with a net profit attributable to the parent company of 22.942 million yuan, an increase of 67.88%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237570973.md"
description: "According to the Zhitong Finance APP, Transtek released its first-quarter report for 2025, with operating revenue of 273 million yuan, a year-on-year increase of 9.90%. The net profit attributable to shareholders of the listed company was 22.942 million yuan, a year-on-year increase of 67.88%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.6489 million yuan, a year-on-year increase of 73.28%. The basic earnings per share were 0.11 yuan"
datetime: "2025-04-25T11:50:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237570973.md)
  - [en](https://longbridge.com/en/news/237570973.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237570973.md)
generator: "portal-rs"
---

# Transtek released its first-quarter performance, with a net profit attributable to the parent company of 22.942 million yuan, an increase of 67.88%

According to the Zhitong Finance APP, Transtek (300562.SZ) released its first-quarter report for 2025, with operating revenue of 273 million yuan, a year-on-year increase of 9.90%. The net profit attributable to shareholders of the listed company was 22.942 million yuan, a year-on-year increase of 67.88%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.6489 million yuan, a year-on-year increase of 73.28%. The basic earnings per share were 0.11 yuan

### Related Stocks

- [300562.CN](https://longbridge.com/en/quote/300562.CN.md)

## Related News & Research

- [11:06 ETEndurance Named to Inc. 5000 for 11th Time, Continuing National Growth](https://longbridge.com/en/news/296124358.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [Asker Healthcare Group buys Baltic medtech distributor Ambercell Solutions](https://longbridge.com/en/news/296306272.md)
- [Thales, Systematic partner to boost Danish air defense capabilities](https://longbridge.com/en/news/296363485.md)
- [08:48 ETLanguageLine TranslateExpress Now Available in the Epic Toolbox](https://longbridge.com/en/news/296230987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**